Genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants: supplemental material

Drug-induced long QT syndrome (diLQTS) is an adverse effect of many commonly prescribed drugs, and

it can increase the risk for lethal ventricular arrhythmias. Genetic variants in pharmacodynamic genes

have been associated with diLQTS, but the strength of the evidence for each of those variants has not yet

been evaluated. Therefore, the purpose of this review was to evaluate the strength of the evidence for

pharmacodynamic genetic variants associated with diLQTS using a novel, semiquantitative scoring system

modified from the approach used for congenital LQTS. KCNE1-D85N and KCNE2-T8A had definitive and

strong evidence for diLQTS, respectively. The high level of evidence for these variants supports current

consideration as risk factors for patients that will be prescribed a QT-prolonging drug.